Competitor Analysis: Herpes Virus Vaccines and Therapeutics
Product description
The present Competitive Intelligence Report about Herpes Virus Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies and small molecules against infection caused by herpes simplex virus (HSV) type 1 and/or type 2 and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders based on the site of infection: oral herpes with the visible symptoms of cold sores or fever blisters, genital herpes and other forms including ocular herpes (keratitis).
Varicella zoster virus (VZV) is another of eight herpes viruses known to infect humans. It commonly causes chicken-pox in children and both shingles and postherpetic neuralgia in adults and rarely in children. Varicella zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3).
The report includes a compilation of marketed and currently active projects in development of vaccines, antibodies and small molecules targeting herpes simplex virus type 1 or type 2 (HSV-1 or HSV-2) and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) for prophylaxis and treatment of oral herpes, genital herpes, chickenpox (varicella) and herpes zoster, respectively. In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Herpes Virus Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies and small molecules against infection caused by herpes simplex virus (HSV) type 1 and/or type 2 and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders based on the site of infection: oral herpes with the visible symptoms of cold sores or fever blisters, genital herpes and other forms including ocular herpes (keratitis).
Varicella zoster virus (VZV) is another of eight herpes viruses known to infect humans. It commonly causes chicken-pox in children and both shingles and postherpetic neuralgia in adults and rarely in children. Varicella zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3).
The report includes a compilation of marketed and currently active projects in development of vaccines, antibodies and small molecules targeting herpes simplex virus type 1 or type 2 (HSV-1 or HSV-2) and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) for prophylaxis and treatment of oral herpes, genital herpes, chickenpox (varicella) and herpes zoster, respectively. In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Product description
- Varicella zoster virus (VZV) Vaccines
- Herpes Simplex Virus (HSV) type 1/2 Vaccines
- HSV Antibodies
- HSV Small Molecules
- Herpetic Keratitis
- Corporate Herpes Virus Vaccine & Therapeutic R&D Pipelines
